U.S. Markets closed

Intercept Pharmaceuticals, Inc. (ICPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
35.69+0.18 (+0.51%)
At close: 4:00PM EST

35.75 +0.06 (0.17%)
After hours: 4:10PM EST

Intercept Pharmaceuticals, Inc.

10 Hudson Yards
37th floor
New York, NY 10001
United States
646 747 1000

Full Time Employees583

Key Executives

NameTitlePayExercisedYear Born
Dr. Mark PruzanskiFounder, CEO, Pres & Director1.3M4.42M1968
Mr. Sandip S. Kapadia CPA, M.B.A.CFO, Treasurer & Principal Accounting Officer738.4kN/A1970
Mr. Jerome B. DursoChief Operating Officer953.9kN/A1968
Mr. Ryan T. SullivanGen. Counsel & Sec.733.98k278.78k1976
Mr. Richard KimPres of U.S. Commercial & Strategic Marketing987.56kN/A1969
Ms. Lisa M. DeFrancescoVP of Investor RelationsN/AN/AN/A
Mr. David FordChief HR OfficerN/AN/A1969
Ms. Lisa Bright MorrisonPres of InternationalN/AN/A1968
Dr. Christian WeyerExec. VP of R&DN/AN/A1970
Dr. Gail CawkwellSr. VP of Medical Affairs, Safety & PharmacovigilanceN/AN/A1962
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. It has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China; and Aralez Pharmaceuticals Canada Inc to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.

Corporate Governance

Intercept Pharmaceuticals, Inc.’s ISS Governance QualityScore as of November 1, 2019 is 5. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 6; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.